

DRS 8/30/82

→ ~~Harriet P.~~
Harriet P.

THE **CANCER** LETTER

Vol. 8 No. 33
Aug. 27, 1982

P.O. Box 2370 Reston, Virginia 22090 Telephone 703-620-4646

©Copyright 1982
The Cancer Letter Inc.
Subscription \$125 year North
America/\$150 yr elsewhere

LITTON LOSES TO PRI ON LARGEST FREDERICK CONTRACT, COMPETING AGAINST HOPKINS FOR SCIENCE PROGRAM

Recompetition and splitting up of the huge contract for operation of the Frederick Cancer Research Facility has been all but completed, with the incumbent, Litton Bionetics Inc., losing the largest of the five contracts being competed and in danger of being shut out entirely.

Program Resources Inc., a 10-year-old Rockville, Md. firm, won the
(Continued to page 2)

In Brief

CANCER PANEL TO MEET IN SEATTLE, HOUSTON, CHICAGO; WISCONSIN'S ROBERT JOHNSON DIES; GOLDIN RETIRES

PRESIDENT'S CANCER Panel will continue holding its meetings around the country, with three of the next four scheduled away from Washington. Next meeting is Sept. 14 in Seattle, 7:30-10:30 p.m., during the XIIIth International Cancer Congress. Topic will be "New Scientific Directions for the National Cancer Program," with presentations by invited scientists. The Panel will meet in Bethesda Nov. 8 for evaluation of suggestions presented during previous meetings and discussion of future agendas. A meeting has been scheduled March 4 in Houston, at M.D. Anderson, with resumption of presentations on grant award procedures and policies, and another meeting on the same subject is tentatively scheduled for Chicago in April. . . . **ROBERT JOHNSON**, leader in cancer research and treatment at the Univ. of Wisconsin and a chief organizer of one of the country's first cancer centers there, died July 30 of cancer. He was 61. He had been chairman of the Central Oncology Group and Wisconsin Oncology Group, associate director of the Wisconsin Clinical Cancer Center and headed the center's cancer control program, and was associated in the development of 5-FU. . . . **ABRAHAM GOLDIN**, who has been at NCI since 1949, retired recently from a career in which he played a prominent role in development of drug screening programs. His studies with methotrexate led to use of high doses of that drug with rescue by citrovorum factor. . . . **THOMAS SLAGA**, who has headed a program in skin carcinogenesis and tumor promotion at Oak Ridge National Laboratory, has been named director of the Univ. of Texas Science Park Research Div., part of the UT Cancer Center. . . . **CARY PRESANT** has left his position as director of the Dept. of Medical Oncology at City of Hope to join the Wilshire Oncology Medical Group in Los Angeles and West Covina. He plans to continue research in liposome diagnosis and treatment of cancer in collaboration with Vestar Research Corp. and California Institute of Technology. . . . **FRED ROSEN**, former associate director for scientific affairs at Roswell Park Memorial Institute, received the sixth annual Dr. William H. Wehr Award in recognition of his distinguished career in cancer research.

CCOP Response So Far
Indicates Applications
To Total 150-200
... Page 3

NDA On VP-16
Goes To Advisory
Committee Sept. 30
... Page 3

DRCCA To Get Name
Change, Three Major
Program Areas
... Page 4

NCI Advisory Group,
Other Cancer Meetings
... Page 6

RFPs Available
... Page 8

investigator in the Hopkins proposal and presumably would be in charge of the program if Hopkins gets the contract.

The single contract with Litton, which reached nearly \$30 million a year before NCI started cutting it back, was the largest awarded in the history of NIH. Competing the five contracts together probably was the most complicated procurement ever attempted by NIH.

David Keefer, deputy director of NCI's Research Contracts Branch, said he was "pleased with the way the Institute conducted itself in this competition. Every rule was complied with, confidentiality of data was protected, and I'm proud of the way we handled the decision making and planning process."

Cart Fretts, director of the NIH Div. of Contracts & Grants, was chief of NCI's Research Contracts Branch when the first contract was awarded to Litton. His office, as well as that of the NIH general counsel, was involved in every phase of the new competition—development of the RFP, determining the competitive range, source selection, documentation, and negotiations. A cost analyst from Fretts' office spent four to six months at FCRF working on the project.

NCI will deal with the contractors through Peter Fischinger, NCI associate director for FCRF; Berge Hamper, general manager for FCRF, who replaced William Payne in that role; and Ronald Defilice, who has been NCI's contract officer there from the start.

CCOP LETTERS RESPONSE INDICATES TOTAL NUMBER OF APPLICATIONS TO BE 150-200

More than 100 letters of intent from organizations planning to submit applications in NCI's Community Clinical Oncology Program had been received by Program Director Robert Frelick through Aug. 23. Letters will be accepted if they are postmarked by that date, the deadline published in the request for applications, so the total number could reach 150 or even 200.

Those numbers indicate that the number of applications which will be submitted probably will not exceed 150, or 200 at the most. NCI staff members and others had speculated that, based on the obvious intense interest in the program, as many as 800 applications might be submitted.

The fact that the number will be less than expected does not mean any lessening of interest. Most of the letters of intent have been from consortia, so the total number of hospitals involved and the geographic coverage probably will be as extensive as predicted earlier.

Frelick said most of the letters are responsive to the RFA and are on the right track. In what is a mild surprise, many of the responders have said they will align with centers as their research bases. NCI officials had expected that a large majority would opt for

cooperative groups and that centers might not play a significant role in the program. They are delighted that that does not seem to be the case, and that some of the comprehensive centers are participating.

"We're getting the right mix of research bases," Frelick said, indicating that cooperative groups were getting their share.

One possibility which had arisen in the long debate over development of the program guidelines was that some community organizations might want to deal with centers out of their immediate areas. NCI insisted that a CCOP could not skip over a nearby center without a valid reason.

Frelick said that the letters so far have not presented a problem in that regard, but "we are going to have some peculiar skips." In those instances, attempts were made to justify using more remote centers as research bases.

FDA TO PRESENT BRISTOL'S VP-16 NDA TO ADVISORY COMMITTEE SEPT. 30

The Food & Drug Administration, moving with unaccustomed swiftness, will present Bristol Laboratories' new drug application for VP-16 to the Oncologic Drugs Advisory Committee at the committee's Sept. 30 meeting.

Bristol filed the NDA only last April, which places VP-16 months or years ahead of the usual FDA pace.

VP-16 has become one of the most widely used investigational anticancer drugs, with demonstrated effectiveness against small cell lung cancer and testicular cancer. NCI made it available free through its Group C mechanism, but the demand was so great that the cost of purchasing it from Bristol for Group C reached \$500,000 a year. NCI decided to stop free distribution until Bristol agreed to supply it at no charge for Group C (*The Cancer Letter*, July 16).

Bristol executives have insisted there is no reason for delaying approval of the NDA and releasing the drug (which Bristol has named Etoposide) for marketing.

Apparently, the widespread use of the drug and perhaps pressures from various sources convinced FDA officials to, for once, abide by the statutory requirement for action on an NDA within 180 days of filing. FDA's usual practice is to kick back the NDA on about day 179, asking for more information and starting the clock all over again.

Bristol's NDA asks for approval of VP-16 for treatment of refractory testicular tumors and small cell anaplastic lung tumors.

Other NDAs which will be submitted to the committee Sept. 30 include:

—Mead Johnson's Ifex (ifosfamide, an analog of cyclophosphamide), for treatment of epidermoid (squamous) adenocarcinoma and large cell lung cancer.

—Lilly Research Laboratories' Eldisine (vindesine)

investigator in the Hopkins proposal and presumably would be in charge of the program if Hopkins gets the contract.

The single contract with Litton, which reached nearly \$30 million a year before NCI started cutting it back, was the largest awarded in the history of NIH. Competing the five contracts together probably was the most complicated procurement ever attempted by NIH.

David Keefer, deputy director of NCI's Research Contracts Branch, said he was "pleased with the way the Institute conducted itself in this competition. Every rule was complied with, confidentiality of data was protected, and I'm proud of the way we handled the decision making and planning process."

Cart Fretts, director of the NIH Div. of Contracts & Grants, was chief of NCI's Research Contracts Branch when the first contract was awarded to Litton. His office, as well as that of the NIH general counsel, was involved in every phase of the new competition—development of the RFP, determining the competitive range, source selection, documentation, and negotiations. A cost analyst from Fretts' office spent four to six months at FCRF working on the project.

NCI will deal with the contractors through Peter Fischinger, NCI associate director for FCRF; Berge Hamper, general manager for FCRF, who replaced William Payne in that role; and Ronald Defilice, who has been NCI's contract officer there from the start.

CCOP LETTERS RESPONSE INDICATES TOTAL NUMBER OF APPLICATIONS TO BE 150-200

More than 100 letters of intent from organizations planning to submit applications in NCI's Community Clinical Oncology Program had been received by Program Director Robert Frelick through Aug. 23. Letters will be accepted if they are postmarked by that date, the deadline published in the request for applications, so the total number could reach 150 or even 200.

Those numbers indicate that the number of applications which will be submitted probably will not exceed 150, or 200 at the most. NCI staff members and others had speculated that, based on the obvious intense interest in the program, as many as 800 applications might be submitted.

The fact that the number will be less than expected does not mean any lessening of interest. Most of the letters of intent have been from consortia, so the total number of hospitals involved and the geographic coverage probably will be as extensive as predicted earlier.

Frelick said most of the letters are responsive to the RFA and are on the right track. In what is a mild surprise, many of the responders have said they will align with centers as their research bases. NCI officials had expected that a large majority would opt for

cooperative groups and that centers might not play a significant role in the program. They are delighted that that does not seem to be the case, and that some of the comprehensive centers are participating.

"We're getting the right mix of research bases," Frelick said, indicating that cooperative groups were getting their share.

One possibility which had arisen in the long debate over development of the program guidelines was that some community organizations might want to deal with centers out of their immediate areas. NCI insisted that a CCOP could not skip over a nearby center without a valid reason.

Frelick said that the letters so far have not presented a problem in that regard, but "we are going to have some peculiar skips." In those instances, attempts were made to justify using more remote centers as research bases.

FDA TO PRESENT BRISTOL'S VP-16 NDA TO ADVISORY COMMITTEE SEPT. 30

The Food & Drug Administration, moving with unaccustomed swiftness, will present Bristol Laboratories' new drug application for VP-16 to the Oncologic Drugs Advisory Committee at the committee's Sept. 30 meeting.

Bristol filed the NDA only last April, which places VP-16 months or years ahead of the usual FDA pace.

VP-16 has become one the most widely used investigational anticancer drugs, with demonstrated effectiveness against small cell lung cancer and testicular cancer. NCI made it available free through its Group C mechanism, but the demand was so great that the cost of purchasing it from Bristol for Group C reached \$500,000 a year. NCI decided to stop free distribution until Bristol agreed to supply it at no charge for Group C (*The Cancer Letter*, July 16).

Bristol executives have insisted there is no reason for delaying approval of the NDA and releasing the drug (which Bristol has named Etoposide) for marketing.

Apparently, the widespread use of the drug and perhaps pressures from various sources convinced FDA officials to, for once, abide by the statutory requirement for action on an NDA within 180 days of filing. FDA's usual practice is to kick back the NDA on about day 179, asking for more information and starting the clock all over again.

Bristol's NDA asks for approval of VP-16 for treatment of refractory testicular tumors and small cell anaplastic lung tumors.

Other NDAs which will be submitted to the committee Sept. 30 include:

—Mead Johnson's Ifex (ifosfamide, an analog of cyclophosphamide), for treatment of epidermoid (squamous) adenocarcinoma and large cell lung cancer.

—Lilly Research Laboratories' Eldisine (vindesine

sulfate) for treatment of children with acute lymphoblastic leukemia in bone marrow relapse who no longer respond to oncovin (vincristine sulfate).

—Lederle Laboratories' methotrexate for treatment of advanced non-Hodgkin's lymphoma with an unfavorable histology at a dosage schedule of three grams per square meter followed by leucovorin calcium at 10 milligrams per square meter starting 24 hours after methotrexate administration then every six hours for 12 doses or as part of the M-BACOD regimen (cycles of bleomycin, doxorubicin, cyclophosphamide, vincristine sulfate, and dexamethasone alternating with three grams per square meter methotrexate and leucovorin calcium).

In what could be a revival of the controversy over adoption of guidelines for clinical evaluation of antineoplastic drugs, FDA has scheduled a discussion on revision of guidelines for the meeting.

The meeting will be held in the Parklawn Building, 5600 Fishers Lane, Rockville, Md., conference rooms G and H, starting at 9 a.m.

DRCCA WILL BECOME DCPC, ORGANIZE INTO THREE MAJOR PROGRAM AREAS

Major changes in the organizational structure of NCI's Div. of Resources, Centers & Community Activities—including changing that name—have been drawn up by Division Director Peter Greenwald, Deputy Director Joseph Cullen, and their staff. NCI Director Vincent DeVita has agreed, and the changes will be submitted to HHS. Until the department approves the changes and the new name, they will not be official.

The new name will be Div. of Cancer Prevention & Control. That could lead to some confusion with the Div. of Cancer Cause & Prevention, and it appears likely that that division's name also will be changed.

DCPC will be organized into three major program areas—the Centers & Community Oncology Program, the Cancer Control Applications Program, and the Preventive Medicine Program. Each will be headed by an associate director. Here is how new and existing branches will be grouped with each program:

Centers & Community Oncology Program—Jerome Yates, associate director.

- Cancer Centers Branch, Donald Pitcairn, acting chief.
- Community Outreach & Rehabilitation, Yates, acting chief.
- Organ Sites Branch, Andrew Chiarodo, chief.
- Breast Cancer Branch, Elizabeth Anderson, acting chief.
- Facilities Branch, Donald Fox, chief.

Cancer Control Applications Program, Cullen, acting AD.

- Research Training Branch, Barney Lepovetsky, chief.

- Behavioral Medicine Branch, Sandra Levy, chief.
- Education Branch, chief being recruited.
- Career Development Branch, chief being recruited.

Preventive Medicine Program, AD being recruited.

- Preventive Medicine Branch, Richard Costlow, chief.
- Chemoprevention Branch, chief being recruited.
- Diet & Cancer Branch, chief being recruited.
- Occupational Cancer Branch, Veronica Conley, acting chief.

Another branch, Cancer Detection, is being considered for the Preventive Medicine Program.

Two branches will be operating under the division director and not in one of the program areas. They are the Cancer Control Science & Support Branch, with Carlos Caban as acting chief, and Biometrics & Operations Research Branch, for which a chief is being recruited. Caban's branch has responsibility for the new Cancer Control Science Program and Cancer Control Research Unit grants.

An intramural program, to include primarily biometrics, chemoprevention, and diet and cancer activities, will be established and probably will be located in the Preventive Medicine Program.

The division's antismoking activities will be the responsibility of the deputy director, and Cullen also will coordinate smoking related research in other NCI divisions.

Move of the Breast Cancer Branch (formerly the Breast Cancer Task Force) from the Div. of Cancer Biology & Diagnosis will soon be completed, and the branch's 12 staff members will be located in the Blair Building in Silver Spring, Md., along with all other DCPC branches. They had been located in the off campus Landow Building in Bethesda.

The Research Training Branch combines the old Research Manpower Branch, headed by Lepovetsky, and the Clinical Manpower Branch, headed by Margaret Edwards, who has retired. The new Education Branch will be responsible for education activities aimed at the public and at health professionals.

The new Career Development Branch will be involved primarily with helping established professionals—MDs, PhDs, MPHs, and perhaps persons in other fields—to develop expertise in cancer control. They will be brought into NCI for limited periods and some may be sent to various institutions to work. "It will be sort of an internal residency to create experts in cancer control," Greenwald said.

The Community Clinical Oncology Program is housed in the Community Outreach & Rehabilitation Branch, with Robert Frelick as CCOP director. Although Yates is serving as acting chief of the branch, he is in the process of recruiting a permanent chief.

Cullen's tenure as acting associate director for the Cancer Control Applications Program is temporary,

and the division will try to recruit a permanent AD for that position. Recruiting to fill other branch chief positions presently either unfilled or held on an acting basis is under way; in some cases, the incumbent acting chiefs are candidates.

NCI's Office of Personnel Management has formally advertised the positions of associate director for preventive medicine and for the chemoprevention, diet and cancer, occupational cancer, community outreach and rehabilitation, and biometrics and operations research branch chiefs.

Qualifications for all but the biometrics/operations branch require that candidates meet the minimum experience and education requirements for medical officers as defined by the U.S. Office of Personnel Management Handbook X-118. These are civil service positions at the GS-15 level with a salary range from \$51,353 to \$65,357, although the current congressional limit on top government salaries is \$57,500. However, physicians may be eligible for the Physician Comparability Pay of up to \$10,000 a year in addition to regular pay.

The biometrics/operations branch chief requirement is that candidates have extensive experience in biostatistics, operations research, computer science, cancer epidemiology or cancer control research. This also is a GS-15 level position, with a salary range of \$46,685 to \$60,689, with the \$57,500 limit.

Job descriptions in the announcements provide some insight on the scope of the positions and activities of the program and branches:

AD for Preventive Medicine—Will direct a multi-million dollar program which has been empowered by congressional mandate to identify research findings of importance for prevention, early detection or diagnosis; to plan and conduct research to develop and ensure validity of measures and to evaluate programs when applied to the general population; to plan and conduct research to analyze, evaluate and refine prevention, detection and diagnosis strategies to assure maximum benefits with the least risk and cost; and to demonstrate prevention, detection and diagnosis activities in cancer centers and communities and selected populations. Candidates should have experience which has demonstrated outstanding leadership in preventive medicine, occupational cancer or epidemiology.

Chemoprevention Branch chief—Will have full responsibility for planning, developing and directing a program in chemoprevention which can be defined as the use of natural or synthetic agents administered to prevent, inhibit, or reverse one or more stages of carcinogenesis; identifying needs for and initiating human chemoprevention trials; developing a process for the oversight, coordination, and systematic investigation of new chemoprevention agents, including new drug development and evaluation of safety and efficacy; and assessing needs for further research pro-

grams relating to diet and the etiology of cancer. Candidates must have extensive experience in nutritional science, pharmacology, epidemiology, or clinical trials.

Diet & Cancer Branch chief—Will have full responsibility for planning, developing, directing and coordinating a research program in diet as it relates to cancer prevention; overseeing cancer, diet and nutrition activities throughout NCI; developing, refining and testing hypotheses of diet in the etiology and prevention of cancer; developing quantitative methods to monitor nutritional intake in large populations and to convert diet into nutrient content; studying baseline dietary data on populations in chemoprevention trials; studying and testing hypotheses related to macronutrients (e.g., fats, fiber, vegetables) and cancer; and assessing strategies for altering diet in relation to cancer risks, weighing scientific knowledge and the impact of such strategies.

Occupational Cancer Branch chief—Will have a major role in the division's effort to bring applied cancer prevention to the occupational setting. Specifically, OCB will plan and conduct research in new methods of prevention and early detection of cancers in individuals at unusually high risk of occupational cancers; develop, implement, and evaluate cancer control methods applicable to occupational cancers which may include methods of reducing exposure, appropriate medical surveillance methods, developing effective means of providing information to workers and management, and investigating potential methods for reducing incidence or for early detection after exposure has occurred; and collaborate with other government agencies, labor and industry organizations, and the national professional and voluntary health organizations involved in occupational cancer.

Community Outreach & Rehabilitation branch—Will have responsibility for developing programs to improve clinical oncology in community settings and fostering integration of community oncology with the National Cancer Program; developing programs to facilitate interactions between community oncologists and regional or national clinical cooperative groups; developing cancer rehabilitation research; helping to establish national cancer control priorities that can be implemented through this program; and coordinating and monitoring the progress of the branch's programs in order to assure measurable public benefit. Candidates must have experience which has demonstrated outstanding leadership in clinical oncology and program management, and cancer control or clinical trials.

Biometrics & Operations Research Branch chief—Will plan, direct, coordinate and evaluate a program of statistical, epidemiological, and operations research activities and automatic data processing services for the division; provide research, development

and implementation of quantitative methods for monitoring progress toward cancer control in the U.S.; provide comprehensive biometric and computer science support and guidance to the division; develop data and provide scientific interpretation for the division director in order to establish program priorities, allocate resources and integrate projects of the division and its interrelation with other NCI divisions; conduct intramural research in biometry, epidemiology, and operations related to cancer prevention and control; and advise the division director, National Cancer Advisory Board and other scientific advisory groups on prevention and control related biometric, epidemiological and operations research activities.

NCI ADVISORY GROUP, OTHER CANCER MEETINGS FOR SEPT., OCT., FUTURE

International Assn. for Comparative Research in Leukemia—Sept. 2-4, Beverly Hills. Contact R. Davis, UCLA Jonsson Comprehensive Cancer Center, 1100 Glendon Ave., Suite 844, Los Angeles 90024.

Oncogenes and Retroviruses: Evaluation of Basic Findings and Clinical Potential—Sept. 2-3, Roswell Park Memorial Institute, Buffalo. Workshop sessions on identification of oncogenes, oncogenes and human neoplasia, transfection, oncogene mapping, and protein products. Contact RPMI, Executive Office RSC No. 530, 666 Elm St., Buffalo 14263, phone 716-845-3020.

7th World Congress Collegium International Chirurgiae Digestivae—Sept. 6-9, Tokyo. Contact T. Aoki, 7th World Congress of CICD, 2nd Dept. of Surgery, Jikei Univ. School of Medicine, 25-8 Nishi Shinbashi 3-chome, Minato-ku, Tokyo 105 Japan.

A Core Curriculum in Oncology Nursing—Sept. 7 (starting a 12 week series), St. Vincent Medical Center, Los Angeles. Co-sponsored by St. Vincent and California Hospital Medical Center Community Hospital Oncology Program. Contact St. Vincent Dept. of Education & Training, phone 213-484-7451.

Coagulation, Cancer & Inflammation—Sept. 8-10, Airlie House, Airlie, Va. Workshop sponsored by NCI and two other NIH institutes. Contact Dr. Anne Ball, Div. of Blood Diseases & Resources, NHLBI, Federal Bldg. Rm 5A12, Bethesda, Md. 20205, phone 301-496-5911.

Tetracarcinoma Cells—Sept. 8-12, Cold Spring Harbor, N.Y. Contact meetings office, Cold Spring Harbor Lab, New York 11724.

XIIIth International Cancer Congress—Sept. 8-15, Seattle. Contact Secretary General of the Congress, Fred Hutchinson Cancer Research Center, 1124 Columbia St., Seattle 98104.

Approaches to Management of Pain—Sept. 9, Goodman's Hall, Oakland, Calif. Contact Despina Johnson, 2844 Summit St., Suite 204, Oakland 94609, phone 415-465-8570.

4th Annual Pharmacy Symposium on Cancer Chemotherapy—Sept. 12-14, Houston Shamrock Hilton Hotel. Contact Sharon Bronson, Dept. of Pharmacy, M.D. Anderson Hospital & Tumor Institute, 6723 Bertner Ave., Houston 77030, phone 713-792-2870.

Diagnosis & Treatment of Selected Gynecologic Malignancies—Sept. 13-Dec. 13, weekly lecture series by Johns Hopkins Div. of Gynecologic Oncology, open to medical profession at no charge. Contact Program Coordinator, Turner 22, 720 Rutland Ave., Baltimore, Md. 21205, phone 301-944-6046.

President's Cancer Panel—Sept. 14, Westin Hotel, Seattle, 7:30 p.m., open.

Papilloma Viruses—Sept. 15-19, Cold Spring Harbor. Contact as above.

Chemical Emergencies in Laboratories—Planning & Response—Sept. 15-16, Frederick Cancer Research Facility. Contact Linda Kesselring, Environmental Control & Research Laboratory, NCI-FCRF, P.O. Box B, Frederick, Md. 21701, phone 301-695-1451.

8th Biannual Morris Hepatoma Symposium—Sept. 16, Westin Hotel, Seattle. Contact Dr. Wayne Criss, Cancer Center, Howard Univ., Washington D.C. 20060, phone 202-636-6351.

Fundamental Problems in Breast Cancer—Sept. 17-18, Univ. of Alberta, Edmonton, contact Cross Cancer Institute, 11560 University Ave., Edmonton, Alberta, Canada T6G 1Z2

1st Convention Societas Europas Pneumologica—Sept. 20-25, Brugge, Belgium. Lung Carcinoma in Europe. Contact Secretary, 1st Conv. SEP, Dept. Pneumology, AZ Sin-Jan, Ruddershove, 8000 Brugge, Belgium.

Poxvirus—Sept. 20-23, Cold Spring Harbor. Contact as above.

Carcinogenesis Studies Using Cultured Human Tissues & Cells—Sept. 20-24, Aspen, Colo. Contact Dr. Curtis Harris, DCCP, NCI, Bldg. 37 Rm 3A17, Bethesda, Md. 20205, phone 301-496-2048.

International Society of Pediatric Oncology—Sept. 21-25, Bern, Switzerland. 14th meeting. Contact Dept. of Child Health, Royal Hospital for Sick Children, St. Michael's Hill, Bristol BS2 8BJ, United Kingdom.

2nd International Congress on Viral Oncology—Sept. 23-26, Naples. Contact Dr. Enrico de Lorenzo, Organizing Secretary, Via Le Elena 17-B, 80122 Naples, Italy.

National Cancer Advisory Board Subcommittee on Environmental Carcinogenesis—Sept. 23, NIH Bldg. 31 Rm 4, 9 a.m., open.

Breast Cancer Task Force—Sept. 23-24, Linden Hill Hotel, Bethesda, Md., Wimbledon Room. Overview of systemic adjuvant therapy for breast cancer, working group meetings on epidemiology, experimental biology, diagnosis, and treatment. Contact Marion Evans, Meeting Coordinator, CSR Inc., 805 15th St. NW, Suite 500, Washington D.C. 20005, phone 202-842-7600.

IVth International Symposium on Nasopharyngeal Carcinoma—Sept. 27-29, Kuala Lumpur, Malaysia. Contact Secretariat, NPC International Symposium, Dept. of ENT, Faculty of Medicine, Univ. of Malaysia, Kuala Lumpur, 22-11, Malaysia.

Society for Immunology—Sept. 27-29, Munster, West Germany. 14th annual meeting. Contact Prof. Dr. E. Macher, Universitat, Hautklinik, Von-Esmarch-Strasse 56, 4400 Munster, Fed. Rep. of Germany.

NCI Div. of Cancer Cause & Prevention Board of Scientific Counselors Subcommittee on Development of Radiation Tables—Sept. 28, NIH Bldg 31 Rm 8, 9 a.m. Scientific issues related to radiation induced cancers.

DCCP Board of Scientific Counselors—Sept. 29-30, NIH Bldg 31 Rm 10, 9 a.m. both days.

5th Oncosurgical Symposium—Sept. 29-Oct. 1, Brno, Czechoslovakia. Czechoslovak Stomatological Society. Problems of metastasizing malignant tumors in the face, complications of jaw and face oncology. Contact J. Bildre, Czech Medical Society, Vitezueho umora 31, 120 26 Prague, Czechoslovakia.

American College of Epidemiology—Sept. 30-Oct. 1, O'Hare Inn, Chicago. Annual meeting. Contact Dr. Curtis Mettlin, Secretary, American College of Epidemiology, Roswell Park Memorial Institute, 666 Elm St., Buffalo N.Y. 14263.

Tumor Registrars Assn. of New England—Sept. 30-Oct. 1, Sheraton-Regal Inn, Hyannis, Mass. Contact Mary Anderson, Cancer Registry, St. Vincent Hospital, 25 Winthrop St., Worcester, Mass. 01604.

Food & Drug Administration Oncologic Drugs Advisory Committee—Sept. 30, Parklawn Bldg. Rm G & H, Rockville, Md., 9 a.m.

Biometry & Epidemiology Contract Review Committee—Oct. 1, NIH Bldg. 31 Rm 8, open 9-9:30 a.m.

Swiss Cancer Congress—Oct. 1-2, St. Gail. Therapeutic modalities in potentially curable malignant tumors. Contact P. Siegenthaler, Swiss Cancer League, Monbijourstr 61, Postfach 2284, 3001 Bern, Switzerland.

National Cancer Advisory Board Subcommittee on Organ Site Programs—Oct. 3, NIH Bldg. 31 Rm 6, 7:30 p.m., open.

National Cancer Advisory Board—Oct. 4-6, NIH Bldg. 31 Rm 6, 8:30 a.m. each day, closed all day Oct. 5.

NCAB Subcommittee on Planning & Budget—Oct. 4, NIH Bldg. 31 Rm 10A52, 7:30 p.m., open.

Interscience Conference on Antimicrobial Agents & Chemotherapy—Oct. 4-6, Miami Beach. Contact R.R. Clark, ASM, 1913 L St. NW, Washington D.C. 20006.

7th European Symposium on Hormones & Cell Regulation—Oct. 4-7, Sainte-Odile, France. Contact Dr. R. Denton, Dept. of Biochemistry, Univ. of Bristol Medical School, Bristol BS8 1TD, Great Britain.

NCAB Subcommittee on Review of Budget & Contracts of the Office of Director—Oct. 6, NIH Bldg. 31 Rm 4, 12:30 p.m.

NCI Div. of Resources, Centers & Community Activities Board of Scientific Counselors—Oct. 7-8, NIH Bldg. 31 Rm 6, 8:30 a.m.

Advances in Pediatric Oncology, Care of the Child & Family—Oct. 7-8, New York City. Contact N. Houlihan, RN, APON Program, 511 E. 80th St., New York 10021.

Cancer in the Elderly: An Interdisciplinary Perspective—Oct. 7-8, Roswell Park continuing education in oncology. Contact Gayle Bersani, RPMI, 666 Elm St., Buffalo 14263.

New York State Cancer Programs Annual Meeting—Oct. 8-9, Roswell Park Memorial Institute, Buffalo. Contact Dr. Edwin Mirand, RPMI, 666 Elm St., Buffalo 14263.

Cancer and the Environment—Oct. 8, Health Education Bldg., Medical College of Ohio, Toledo. Presentations on identification of carcinogens, mechanisms of action, prevention, screening. Contact Northwest Ohio Cancer Network, phone 419-381-3717.

5th South African International Radiological Congress—Oct. 8-15, Johannesburg, Republic of South Africa. Contact P. Reichmann, POB 2251, Johannesburg, 200.

9th UICC Training Course in Cancer Research—Oct. 10-21, Rehovot, Israel. Contact Prof. Gideon Berke, Dept. of Cell Biology, Weitzmann Institute, Rehovot 76100.

12th Symposium on Neuroradiologicum—Oct. 10-16, Bethesda. Contact Dr. G. diChiro, Neuroradiology Computed Tomography Section, Clinical Center, Bldg. 10 Rm 11N240, Bethesda, Md. 20205, phone 301-496-6801.

NCI Div. of Cancer Treatment Board of Scientific Counselors—Oct. 11-12, NIH Bldg. 31 Rm 10, 8:30 a.m. both days, closed Oct. 11, 5-7 p.m.

Sixth Annual Cancer Symposium—Oct. 11-13, Vacation Village Hotel, San Diego. Sponsored by Scripps Memorial Hospital. Contact Nomi Feldman, 3770 Tansy, San Diego 92121, phone 714-453-6222.

Cancer Symposium for Nurses—Oct. 11-13, Islandia Hyatt House, San Diego. Contact Nomi Feldman, address above.

4th World Congress on Diseases of the Chest—Oct. 11-13, Toronto. Contact A. Soffer, American College of Chest Surgeons, 911 Busse Highway, Park Ridge, Ill. 60068.

Southeastern Cancer Research Assn.—Oct. 14-15, Quality Inn, Gatlinburg, Tenn. Contact Dr. Wayne Criss, Cancer Center, Howard Univ., Washington D.C. 20060.

Symposium on Dentistry and Cancer—Oct. 14, Roswell Park continuing education in oncology.

Piedmont Oncology Assn. Third Annual Conference—Oct. 15-16, Inn on the Plaza, Asheville, N.C. Contact POA, Bowman Gray School of Medicine, Oncology Research Center, 300 S. Hawthorne Rd., Winston-Salem, N.C. 27103, phone 919-748-4464.

10th World Congress of Gynecology & Obstetrics—Oct. 17-

22, San Francisco. Contact American College of Ob/Gyn, POB 23578, Washington D.C. 20024.

Chromosomes and Cancer: From Molecules to Man—Oct. 18-19, Univ. of Chicago. Fifth annual Bristol-Myers symposium on cancer research. Contact Dr. Janet Rowley or Dr. John Ulmann, Univ. of Chicago Cancer Research Center, Box 444, 950 E. 59th St., Chicago 60637.

Cancer Control Grant Review Committee—Oct. 18-19, NIH Bldg 31 Rm 8, open Oct. 18, 8:30-9 a.m.

Cancers Induced by Therapeutic Modalities—Oct. 18, Paris. Contact Mrs. Berthomeau, Institut Curie, 26 rue d'Ulm, 75231, Paris, Cedex 05, France.

German and Swiss Radiation Protection Union—Oct. 18-22, Munich. Contact Gesellschaft fur Strahlen und Umweltforschung GmbH, Ingolstradter Landstr. 1, 8042 Neuherberg, Fed. Rep. of Germany.

7th International Symposium of the World Assn. of Veterinary Microbiologists, Immunologists, and Specialists in Infectious Diseases—Oct. 18-21, Barcelona. Contact Dr. Juan Plana Duran, Gran Via de les Corts Catalanes, 794 bajos (Chaflan Lepanto), Barcelona 13, Spain.

NCI Div. of Cancer Biology & Diagnosis Board of Scientific Counselors—Oct. 20-22, NIH Bldg. 31 Rm 10, first day; Rm 8 following days, 9 a.m.

9th Annual Symposium on Dermatopathology: Pitfalls in Diagnosis of Malignant Melanoma—Oct. 21-23, New York. Contact Dr. Bernard Ackerman, Dermatopathology Section, NYU Medical Center, 530 First Ave., New York 10016, phone 212-340-7250.

Computers in Medical Practice—Oct. 21, Roswell Park continuing education in oncology.

Nutrition and Cancer—Oct. 22-23, Chapel Hill, N.C. Contact Dr. William Heizer, Cancer Research Center, Box 30, MacNider Bldg., Univ. of North Carolina, Chapel Hill 27514.

10th International Tutorial on Clinical Cytology—Oct. 23-30, Vienna. Contact C.M. Weil Center for Continuing Education, Univ. of Chicago, 1307 E. 60th St., Chicago 60637.

Interscience Conference on Antimicrobial Agents & Chemotherapy—Oct. 24-26, Las Vegas, Nev. Contact R.R. Clark, ASM, 1913 L St. NW, Washington D.C. 20006.

American Society of Therapeutic Radiologists—Oct. 24-31, Orlando. Annual meeting. Contact S.A. Aubin, 20 N. Wacker Dr., Rm 2920, Chicago 60606.

1st World Congress on Trophoblast Neoplasms—Oct. 25-27, Lagos, Nigeria. Contact Medical College of Wisconsin, Dept. of Ob/Gyn, 8700 W. Wisconsin Ave., Milwaukee 53226.

FUTURE MEETINGS

Cancer Nursing: Today and Tomorrow—Nov. 1-2, Johns Hopkins Medical Institutions, Baltimore. Contact Program Coordinator, Turner 22, 720 Rutland Ave., Baltimore, Md. 21205, phone 301-955-6046.

Controversies in the Management of Early Breast Cancer—Nov. 17, Biltmore Hotel, Los Angeles. Contact Bonnie Van-Waardenburg, Hospital of the Good Samaritan, 616 S. Witmer St., Los Angeles 90017, phone 213-977-2345.

Role of Nutrition in Preventing and Treating Cancer—Dec. 9-10, Washington D.C. Second annual Bristol-Myers Symposium on Nutrition Research. Contact Ann Wyant or Kathryn Bloom, phone 212-546-4337.

International Assn. for Breast Cancer Research—March 20-24, 1983, Hilton Hotel, Denver. Contact Dr. Marvin Rich, AMC Cancer Research Center, 6401 W. Colfax Ave., Lakewood, Colo. 80214.

Carcinogenesis, Immunology and Transplantation: Environmental Host Factors—April 25-27, Roswell Park Memorial Institute. Current information on certain aspects of cancer and their interrelationship with transplantation. Contact Dr. Gerald Murphy, Director, RPMI, 666 Elm St., Buffalo, N.Y. 14263.

RFPs AVAILABLE

Requests for proposal described here pertain to contracts planned for award by the National Cancer Institute unless otherwise noted. Write to the Contracting Officer or Contract Specialist for copies of the RFP, citing the RFP number.

NCI listings will show the phone number of the Contracting Officer or Contract Specialist who will respond to questions. Address requests for NCI RFPs to the individual named, the Blair Building room number shown, National Cancer Institute, 8300 Colesville Rd., Silver Spring, Md. 20910. RFP announcements from other agencies reported here will include the complete mailing address at the end of each.

RFP NCI-CO-33855-38

Title: *Screening, indexing and abstracting (SIA) of cancer-related literature for input to the ICRDB program databases*

Deadline: Oct. 25

NCI intends to issue an RFP for a small business firm to screen, index and abstract cancer related articles and documents for the International Cancer Research Data Bank Program of the Office of International Affairs.

ICRDB maintains and updates an online database called CANCERLIT which contains abstracts of published cancer literature. ICRDB will prepare an "Express" database which will contain rapidly processed abstracts of high quality cancer information for immediate availability to the clinician and researcher. Other abstracts will be processed at a slower rate for entry to a more archival and comprehensive database. This contract is primarily for the screening, indexing, and abstracting of documents for entry into both the "express" and "archived" databases.

Records prepared under this contract must be indexed using MeSH vocabulary by individuals who have completed the formal MeSH training course of the National Library of Medicine.

Proposals must include statements which document that the offeror has prepared indexed abstracts of biomedical literature and bibliographic records on magnetic tapes/discs which are suitable for use in on-line databases at the level of at least 5,000 abstracts per year within the past two years.

The proposed procurement listed herein is a total set aside for small business concerns. A small business for purposes of this procurement is a firm, including its affiliates, that is independently owned and operated, is not dominant in the field of operations in which it is bidding on government contracts, and whose average receipts for its preceding three fiscal years do not exceed \$4 million dollars. This project is for a four year period.

RFP NCI-CO-33856-38

Title: *Screening, indexing, and keying (SIK) of cancer-related literature for input to the ICRDB program databases*

Deadline: Oct. 27

NCI intends to issue an RFP for a small business firm to screen, index and key cancer related articles and documents for the International Cancer Research Data Bank Program of the Office of International Affairs.

ICRDB maintains and updates an online database called CANCERLIT which contains abstracts of published cancer literature. ICRDB will prepare an "express" database which will contain rapidly processed abstracts of high quality cancer information for immediate availability to the clinician and researcher. Other abstracts will be processed at a slower rate for entry to a more archival and comprehensive database. This contract is primarily for the screening, indexing, and keying of input records from documents which already have prepared abstracts that can be used by the ICRDB program.

Records prepared under this contract must be indexed using MeSH vocabulary by individuals who have completed the formal MeSH training course of the National Library of Medicine.

Proposals must include statements which document that the offeror has prepared indexed abstracts of biomedical literature and bibliographic records on magnetic tapes/discs which are suitable for use in on-line databases at the level of at least 5,000 abstracts per year within the past two years.

The proposed procurement listed herein is a total set aside for small business concerns. A small business for purposes of this procurement, is a firm, including its affiliates, that is independently owned and operated, is not dominant in the field of operations in which it is bidding on government contracts, and whose average receipts for its preceding three fiscal years do not exceed \$4 million. This project is for a four-year period.

Contract Specialist for above

two RFPs: Barbara Mercer
RCB, Blair Bldg. Rm. 332
301-427-8877

NCI CONTRACT AWARDS

Title: Lung cancer control—detection and therapy, continuation

Contractor: Johns Hopkins Univ. School of Medicine, \$3,224,601.

The Cancer Letter

Editor Jerry D. Boyd

Published forty-eight times a year by The Cancer Letter, Inc., P.O. Box 2370, Reston Virginia 22090. Also publisher of The Clinical Cancer Letter. All rights reserved. None of the content of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means (electronic, mechanical, photocopying, recording or otherwise) without the prior written permission of the publisher. Violators risk criminal penalties and \$50,000 damages.